19 results about "Immunologic Diagnosis" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-terminal deoxynucleotidyl transferase (TdT) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody disclosed by the invention can specifically recognize TdT protein naturally expressed in cells and tissues, has the advantages of high specificity, high affinity, high sensitivity and the like when being used for immunoblotting, immunohistochemistry and other immunodetection systems, is beneficial to reducing false positive and false negative rates in pathological diagnosis, improves the accuracy of immunodiagnosis, and has a good application prospect. The method has wide application potential in the field of immunological detection of living biological samples. In addition, the antibody disclosed by the invention has cross-species reaction characteristics on homologous TdT proteins of human, mice and rats, so that the application scene of the antibody is greatly expanded.

The present invention belongs to the field of antibody technology, and in particular relates to monoclonal antibodies, antibody conjugates and applications thereof against p21 proteins. The amino acid sequences of the complementary determining regions CDR1-3 on the light chain variable region of the monoclonal antibody are shown as SEQ ID NO.3-5, respectively; the amino acid sequences of the complementary determining regions CDR1-3 on the heavy chain variable region are shown as SEQ ID NO.8-10, respectively. The monoclonal antibody provided by the present invention can specifically recognize p21 proteins expressed by human cells and tissues, has good affinity for binding to p21 proteins, high recognition sensitivity, and strong anti-interference ability, is suitable for immunodiagnostic analysis of p21 proteins in tissues / cells, and has broad application prospects and good market prospects in clinical diagnosis and scientific research detection. In addition, the antibody has cross-reactivity to homologous p21 proteins of humans, rats and mice, and has certain applicability to the detection of rat and mouse p21 proteins.

The all-in-one cartridge (100) for on-site diagnosis provided in the present disclosure relates to an integrated cartridge capable of sample solution injection and detection. The cartridge is equipped with a sample injection cap (13), a sample injection port (14), a tip (12), a 2D barcode (15), a sample chamber (22), a buffer chamber (23), a mixing chamber (25), a washing chamber (26), and a PCR chamber (28) for performing PCR. The cartridge (100) can be used for molecular diagnosis, and a diagnostic device therefor can be selectively used for molecular diagnosis, immunodiagnosis and rapid diagnosis.

The invention discloses an application of TMEM106A as a target spot in preparation of a diagnostic kit and a targeted therapeutic drug. Relates to the technical field of immunodiagnosis. Specific applications are provided. The invention discloses a key effect of TMEM106A in podocyte injury related to preeclampsia. TMEM106A is significantly down-regulated in urine of a PE patient, is closely related to podocyte injury and inflammatory response, and can be used as an early noninvasive diagnostic marker; meanwhile, the targeted podocyte up-regulation TMEM106A has remarkable anti-inflammatory and kidney protection effects, and a theoretical basis and practical feasibility are provided for targeted therapy of PE-related podocyte injury. The invention provides a new way for early precise diagnosis and intervention strategy of PE, and has wide clinical application prospect.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human prostate specific membrane antigen (PSMA) antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the antibody are respectively shown as SEQ ID NO.8-10. The antibody with the complementarity determining region sequence provided by the invention can specifically recognize PSMA expressed by cells and tissues, has good affinity in combination with the PSMA, has high recognition sensitivity, can effectively resist the interference of complex non-target protein components in the cells / tissues, has no specific combination with non-target antigens, is suitable for immunological detection of the PSMA, and has good application prospects. The kit is especially suitable for western blot detection and immunohistochemical methods, and can reduce the occurrence rate of false positive and false negative results and improve the accuracy of immunodiagnosis.

The application provides a Bola type surfactant-based blocking agent, which can be used for modifying various object surface materials, especially the surface of a carrier material for immune diagnosis, so that the non-specific adsorption of the carrier material is reduced, and the sensitivity and signal-to-noise ratio of a reagent are improved. Compared with traditional blocking agents, the Bola type surfactant-based blocking agent provided by the application not only has the excellent characteristics of traditional surfactant blocking agents, but also has increased repulsion to non-specific molecules and more compact blocking due to the rigid hairpin structure after combination.

The invention relates to the field of in-vitro immunodiagnosis detection, in particular to an IgG antibody of mumps virus, a recombinant IgM antibody and application. Wherein the IgG antibody comprises a heavy chain constant region, a light chain constant region, and a heavy chain variable region and a light chain variable region of the IgG monoclonal antibody which is specifically combined with the mumps virus, and the IgG monoclonal antibody is of a mouse source or a rabbit source. According to the present invention, the IgG antibody is modified to obtain the recombinant IgM antibody, and the IgG antibody and the recombinant IgM antibody are not only suitable for the chemiluminescence method, but also show the expected sensitivity amplification factor in other immunological detection methods, such that the low-abundance detection of the specifically bound mumps virus can be easily achieved.

The present disclosure provides a fusion protein, a conjugate containing the same, a kit and use, belonging to the technical field of immunodiagnosis. The fusion protein of the present disclosure comprises a protein tag and a protein part, the fusion protein containing the protein tag has improved activity or specificity, and the fusion protein is used for immunodetection, which can improve the sensitivity or specificity of immunodetection.

The invention provides a tumor immunodiagnosis and treatment drug AC484-PFC and a preparation method and application thereof, the tumor immunodiagnosis and treatment drug AC484-PFC comprises a drug-loading membrane, glycerin and a perfluorinated compound PFC are wrapped in the drug-loading membrane, and the drug-loading membrane comprises AC484, phospholipid and cholesterol. The medicine has the characteristics of high stability and strong medicine carrying capacity, and can be delivered to tumor tissues through multiple ways such as respiratory tracts or veins. The AC484-PFC prepared by the invention is dynamically monitored through a 1H / 19F magnetic resonance imaging technology, the accumulation and distribution of drugs in a living body are evaluated in real time, in-vivo and non-invasive evaluation of a tumor development state is supported, immunotherapy is accurately guided, and the tumor treatment effect is remarkably improved.

Based on a monkey pox virus immunodiagnosis technology based on up-conversion and long-afterglow nanoparticles, the preparation method comprises the following steps: preparing the long-afterglow and up-conversion nanoparticles by adopting a hydrothermal method and a solvothermal method respectively, and constructing the antibody-modified UCNP and PLNP nano probe by utilizing an EDC-NHS cross-linking system after carboxylation modification. The two nanoprobes and an antigen form an immune complex in a double antibody sandwich mode, the UCNPs is excited to emit light at the wavelength of 980 nm, the UCNPs and the PLNPs generate an LRET effect, an obvious signal peak is detected at the wavelength of 700 nm, and the fluorescence signal intensity is in direct proportion to the antigen content. The detection technology is portable and high in sensitivity, the detection limit is as low as the pg / ml level, and the monkey pox virus antigen standard substance can be detected in the range of 1 mg / ml to 1 ng / ml. According to the immunodetection technology provided by the invention, the detection of various pathogens can be realized by replacing antibody combinations aiming at different antigen epitopes, and the application potential in the aspect of infectious disease diagnosis is huge.

The invention relates to the technical field of medicine, in particular to a lymphocyte preserving fluid, a preparation method and application in sample pretreatment, the lymphocyte preserving fluid is prepared from the following components in parts by mass: 90-100 parts of a Tris-HC1 buffer solution, 10-15 parts of trehalose, 0.01-0.03 part of trichostatin A, 0.3-0.5 part of a nuclease inhibitor and the like. Through collaborative design of a composite buffer system and a functionalized nano-material and in combination with a multi-stage activity protection technology, precise isolation of cell metabolism regulation and external interference factors is realized, the treatment efficiency of a complex sample is improved, the preservation time of a key biomarker is prolonged, and the adaptability in an extreme environment is enhanced; the integration of an innovative preparation process and an intelligent quality control module provides reliable support for immunologic diagnosis and treatment, rare cell research and telemedicine, and has wide clinical application and scientific research transformation prospects.

The present invention relates to an immune device for determining the presence or absence of pregnancy or abnormal pregnancy, and more specifically, to an immune device capable of recognizing both intact hCG and βcf hCG. R This immunological device contains a multi-linked anti-hCG monoclonal antibody, and can separately detect intact hCG and βcf hCG contained in the sample, including two detection lines and a control line.By quantifying the ratio of the color intensity of βcf hCG to the color intensity of intact hCG and βcf hCG (the distribution ratio of βcf hCG), it can accurately and quickly determine the number of weeks of pregnancy, normal pregnancy, ectopic pregnancy, and abnormal pregnancy including blighted oocytes.

The invention belongs to the technical field of antibody preparation, and particularly relates to an antibody for resisting human cathepsin B, an antibody pair, a kit and application thereof. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The invention provides two antibodies capable of specifically, accurately, sensitively and reliably detecting the content of human cathepsin B, an antibody pair composed of the antibodies and a kit containing the antibodies or the antibody pair, and the antibodies or the antibody pair have good practical application value in the field of immunodiagnosis and treatment of CTSB abnormal diseases.

The invention belongs to the technical field of in-vitro diagnosis, and discloses a preparation method of a high-sensitivity chemiluminescent reagent for in-vitro diagnosis, which is characterized in that an electron donating group (methoxyl) and a steric hindrance group (tert-butyl) are introduced on the basis of a traditional luminol structure, so that the electron density and stability of a molecular conjugated system are remarkably enhanced, and the chemiluminescent reagent has high sensitivity. The light-emitting quantum efficiency and the oxidation resistance of the substrate are improved. Meanwhile, Co < 2 + > or Ni < 2 + > is adopted as a transition metal catalytic center and cooperates with a phenol enhancer to construct a two-channel free radical enhancement system, the luminol oxidation luminescence process is effectively accelerated, and the luminescence duration is prolonged. The preparation method of the reagent comprises the following steps: synthesizing a luminol derivative, preparing a metal catalyst solution and a phenol enhancer solution, and mixing according to an optimized ratio. The luminescent system shows high signal-to-noise ratio and excellent repeatability in low-concentration biomarker detection, the lowest detection limit is less than 1pg / mL, and the luminescent system is suitable for high-sensitivity in-vitro immunodiagnosis analysis.

The invention discloses a CBA method reagent for detecting a GFAP antibody through fusion expression of GFAP alpha and GFAP epsilon and a detection method, and belongs to the technical field of neural immunodiagnosis. The fusion protein sequentially comprises the following functional domains: secretion signal peptide, a GFAP alpha partial sequence, a GFAP epsilon partial sequence, a transmembrane sequence and a fluorescent label. The core of the invention lies in that a fusion cell is constructed by using partial sequences of GFAP alpha and GFAP epsilon, and co-expression is realized in a host cell through a co-transfection technology, so that the sensitivity and specificity of detecting a CFAP antibody in a CBA method (cellular immunofluorescence method) can be remarkably improved.

The invention relates to the technical field of antibodies, in particular to an OXA-23 enzyme monoclonal antibody and application thereof. When the OXA-23 enzyme monoclonal antibody is used for immunodetection, the OXA-23 enzyme monoclonal antibody has high sensitivity, high affinity to antigens and good specificity, is suitable for being used as an immunodiagnosis reagent, can be used for in-vitro diagnosis of OXA-23 enzyme, and has a wide application prospect.

The invention relates to the technical field of immunodiagnosis, in particular to application of TRPM2 in evaluation of viral pneumonia prognosis. The TRPM2 is used as a key immune marker, a novel detection system for viral pneumonia disease course monitoring and disease assessment is constructed, disease progression and treatment response can be accurately and dynamically reflected in the early stage, and the accuracy of viral pneumonia clinical risk assessment and intervention decision is remarkably improved.

The application discloses a CBA method reagent for detecting GFAP antibody by fusing expression of GFAP alpha and GFAP epsilon and a detection method, and belongs to the technical field of neuroimmunological diagnosis. The reagent comprises a host cell which is recombined to express a fusion protein. The fusion protein comprises the following functional domains in sequence: a secretion signal peptide, a GFAP alpha partial sequence, a GFAP epsilon partial sequence, a transmembrane sequence and a fluorescent label. The core of the application is that the fusion cell is constructed by using the partial sequences of GFAP alpha and GFAP epsilon, and the co-expression is realized in the host cell by using the co-transfection technology. The sensitivity and the specificity of the detection of the CFAP antibody in the CBA method (cellular immunofluorescence method) can be significantly improved.

The present invention relates to a composition and imaging technology for evaluating the immune response of T cells, and in particular, to the technological field of T cell activation analysis and infectious disease diagnosis using lens-free shadow imaging. According to the present invention, activation of T cells can be effectively induced through a T cell activation composition composed of a specific component combination (PHA, PMA, ionomycin, etc.), and T cell activation-specific image parameters (MMD_SD etc.) can be acquired from the activated T cells through lens-free shadow imaging technology. Moreover, since a T cell activity analysis device and method using these parameters exhibit significant performance in diagnosing the presence or absence of latent tuberculosis infection, the present invention has the effect of providing a biological composition that can be used for T cell functional analysis, creating a non-labeling immunodiagnostic platform, and presenting a novel analytical index for LTBI diagnosis.